{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:47:39Z","timestamp":1760852859761},"reference-count":15,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            RWJ-54428 (MC-02,479) is a new cephalosporin with activity against resistant gram-positive organisms, including methicillin-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            , vancomycin-resistant enterococci, and penicillin-resistant\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            . The in vivo efficacy of RWJ-54428 was evaluated against gram-positive bacteria in four mouse models of infection. RWJ-54428 was effective in vivo against methicillin-susceptible and -resistant\n            <jats:italic>S. aureus<\/jats:italic>\n            in a mouse model of sepsis, with 50% effective doses being similar to those of vancomycin. In a single-dose neutropenic mouse thigh model of infection, RWJ-54428 at 30 mg\/kg of body weight showed activity similar to that of vancomycin at 30 mg\/kg against a strain of methicillin-resistant\n            <jats:italic>S. aureus<\/jats:italic>\n            . RWJ-54428 also showed a prolonged in vivo postantibiotic effect in this model. In a mouse model of pneumonia due to a penicillin-susceptible strain of\n            <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n            , RWJ-54428 displayed efficacy and potency superior to those of penicillin G and cefotaxime. In a mouse model of pyelonephritis due to\n            <jats:italic>Enterococcus faecalis<\/jats:italic>\n            , RWJ-54428 had bactericidal effects similar to those of vancomycin and ampicillin, but at two- to threefold lower total daily doses. These studies show that RWJ-54428 is active in experimental mouse models of infection against gram-positive organisms, including strains resistant to earlier cephalosporins and penicillin G.\n          <\/jats:p>","DOI":"10.1128\/aac.47.1.43-47.2003","type":"journal-article","created":{"date-parts":[[2002,12,24]],"date-time":"2002-12-24T04:39:08Z","timestamp":1040704748000},"page":"43-47","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["In Vivo Antibacterial Activity of RWJ-54428, a New Cephalosporin with Activity against Gram-Positive Bacteria"],"prefix":"10.1128","volume":"47","author":[{"given":"David C.","family":"Griffith","sequence":"first","affiliation":[{"name":"Essential Therapeutics Inc., Mountain View, California 94043"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Harford","sequence":"additional","affiliation":[{"name":"Essential Therapeutics Inc., Mountain View, California 94043"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Williams","sequence":"additional","affiliation":[{"name":"Essential Therapeutics Inc., Mountain View, California 94043"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ving J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Essential Therapeutics Inc., Mountain View, California 94043"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.","family":"Dudley","sequence":"additional","affiliation":[{"name":"Essential Therapeutics Inc., Mountain View, California 94043"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.5.1422-1430.2001"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000417619","volume":"42","year":"1989","unstructured":"Collins, M. S., A. Edwards, R. E. Roby, N. S. Mehton, and D. Ladehoff. 1989. Pseudomonas immune globulin therapy improves survival in experimental Pseudomonas aeruginosa bacteremic pneumonia. Antibiot. Chemother.42:184-192.","journal-title":"Antibiot. Chemother."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.7326\/0003-4819-106-6-900","volume":"106","year":"1987","unstructured":"Craig, W. A., and B. Vogelman. 1987. The postantibiotic effect. Ann. Intern. Med.106:900-902.","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jac\/31.2.245","volume":"31","year":"1993","unstructured":"Hanberger, H., E. Svensson, M. Nilsson, L. E. Nilsson, E. G. Hornsten, and R. Maller. 1993. Effects of imipenem on Escherichia coli studied using bioluminescence, viable counting and microscopy. J. Antimicrob. Chemother.31:245-260.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.7164\/antibiotics.53.1272","volume":"53","year":"2000","unstructured":"Hecker, S. J., T. W. Glinka, A. Cho, Z. J. Zhang, M. E. Price, S. Chamberland, D. Griffith, and V. J. Lee. 2000. Discovery of RWJ-54428 (MC-02,479), a new cephalosporin active against resistant gram-positive bacteria. J. Antibiot.53:1272-1281.","journal-title":"J. Antibiot."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.10.1399"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.321-326.2002"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.7164\/antibiotics.46.88","volume":"46","year":"1993","unstructured":"Mine, Y., Y. Watanabe, H. Sakamoto, K. Hatano, Y. Wakai, T. Kamimura, S. Tawara, S. Matsumoto, F. Matsumoto, and S. Kuwahara. 1993. In vivo antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin. J. Antibiot.46:88-98.","journal-title":"J. Antibiot."},{"key":"e_1_3_2_10_2","unstructured":"National Committee for Clinical Laboratory Standards. 2000. Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically 4th ed. Approved standard M7-A4 vol. 17 no. 2. National Committee for Clinical Laboratory Standards Wayne Pa."},{"key":"e_1_3_2_11_2","first-page":"797","volume":"3","year":"1977","unstructured":"Pasiello, A. P., J. M. Essigman, and G. N. Wogan. 1977. Rapid and accurate determination of median lethal dose (LD50) and its error with a small computer. J. Toxicol. Environ.3:797-809.","journal-title":"J. Toxicol. Environ."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/jac\/dkf020","volume":"49","year":"2002","unstructured":"Swenson, J. M., and F. C. Tenover. 2002. In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide-intermediate Stapylococcus aureus. J. Antimicrob. Chemother.49:845-850.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_13_2","first-page":"1790","volume":"82","year":"1975","unstructured":"Teng, N. H., H. S. Kaplan, J. M. Herbert, C. Moore, H. Douglas, A. Wunderlich, and A. I. Braude. 1975. Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc. Natl. Acad. Sci. USA82:1790-1794.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Tenover F. C. 1999. Implications of vancomycin resistant Staphylococcus aureus . J. Hosp. Infect. 43 (Suppl.) : S3-S7.","DOI":"10.1016\/S0195-6701(99)90060-9"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/157.2.287"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432603"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.1.43-47.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.1.43-47.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:01:19Z","timestamp":1645466479000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.1.43-47.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1128\/AAC.47.1.43-47.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.1.43-47.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]},"assertion":[{"value":"2002-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-09-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}